Almost 90% of new PCa are localized and they are clinically classified in three risk groups, based on the serum prostate-specific antigen (PSA) levels, local clinical stage and histological aggressiveness provided by the Gleason Score (GS): high risk, intermediate risk, low risk and very low risk [2]. This evidence concerns the gene KLK3 and posterior cortical atrophy.